Review
Open access
Aug 2026
Oncogenic KRAS in Cancer Immunotherapy: From Oncogenic Signaling to Tumor-Immune Ecosystem Regulation
Current evidence supports a paradigm in which KRAS functions not only as an oncogenic driver but also as a regulator of tumor-immune interactions, shaping therapeutic responsiveness and providing opportunities for biomarker-guided and combination-based immunotherapy in KRAS-mutant cancers.
M. Ashrafizadeh, Noushin Nabavi, Yifei Xu
· Cancer Biome and Targeted Th... · 0 citations